China’s state-run Global Times on Thursday reported that BioNTech, the German company that partnered with American company Pfizer to produce its coronavirus vaccine, is “considering to evaluate” mixing its mRNA product with the vaccine manufactured by China’s Fosun Pharma.
This consideration and evaluation is part of the Chinese government’s approval process for the Pfizer vaccine. BioNTech CEO Ugur Sahin said his company’s talks with Chinese officials have been “encouraging.”
According to the Global Times, the BioNTech vaccine will probably be “landing” soon in Shanghai, where Fosun Pharma is based, and also hosts a sizable population of foreigners who “want a BioNTech’s shot for vaccine recognition when returning to their homeland.” Delivery drills for vaccine supply chains in China are reportedly underway. Chinese state media outlets make a point of not referring to the vaccine by the American partner company name.
Chinese Center for Disease Control and Prevention immunologist